Secukinumab

• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting
  2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
• STARS (Secukinumab in TAkayasu ARteritiS) Recruiting
  2024-516215-24-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Proactive TDM versus standard use of biologics in psoriasis (HELIOS) Recruiting
  2023-509637-39-00 Phase IV 1 country Universitair Ziekenhuis Gent
• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i… Recruiting
  2023-504417-67-00 Phase IV 7 countries Novartis Pharma AG
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat… Ended
  2024-513348-27-00 Phase III 1 country Celltrion Inc.
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended
  2023-508077-85-00 Phase III 10 countries Novartis Pharma AG
• A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended
  2023-509320-17-00 Phase IV 9 countries Novartis Pharma AG
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502068-19-00 Phase III 6 countries Novartis Pharma AG
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 Phase III 6 countries Novartis Pharma AG
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended
  2022-501895-25-00 Phase III 15 countries Novartis Pharma AG
• Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab) Ended
  2023-505711-20-00 Phase IV 1 country Tartu University Hospital
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 Phase III 1 country Novartis Pharma GmbH
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended
  2024-510744-31-00 Phase III 17 countries Novartis Pharma AG
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Ended
  2023-508956-20-00 Phase III 14 countries Novartis Pharma AG

Showing 1–16 of 16 trials